

SESSION 1:

Introduction

18:00-18:10

**Welcome and introduction &
Mylan commitment to psychiatry**

M. Grazia Giustra

SESSION 2:

Optimising TRS early diagnosis and patient outcomes

18:10-18:20

Challenges and unmet needs in TRS.

Why education is important

Prof. Christoph Correll

Q&A

18:20-18:50

**Summary of consensus guidelines on TRS &
clozapine usage and the benefits of early diagnosis
and intervention in TRS**

Prof. Oliver Howes

Q&A

18:50-19:20

TRS treatment with clozapine

Prof. Christoph Correll

Break 10 minutes

SESSION 3:

Clinical experience with Leronex

19:30-19:50

**How to utilize clozapine serum assay monitoring to
improve clinical outcomes (UK CPMS)**

David Klitchen

19:50-20:30

Clinical case on early onset TRS

Prof. Oliver Howes

**Clinical case on worsening of the patients
after stopping clozapine**

Prof. Christoph Correll

20:30

Closure

Speech 3, 4, 5 include Q&A

**From TRS Early Diagnosis
to Clozapine Treatment
Management**

Virtual Workshop

14th October
18.00 - 20.30 CET

Know the Speakers



Prof. Christoph Correll

Charité University, Berlin, Germany;
Zucker School of Medicine at Hofstra/Northwell,
New York, USA

Prof. Dr. med Christoph Correll is Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Furthermore, he is Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

Professor Correll's research and clinical work focus on the identification, characterisation and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, the risk–benefit evaluation of psychotropic medications and the interface between psychiatry and medicine.



Prof. Oliver Howes

BM BCh, MRCPsych, PhD,
DM, FMedSci

Oliver Howes is Professor of Molecular Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, King's College, London and Programme Leader at the MRC London Institute of Medicine, Imperial College, London. His clinical work is as Consultant Psychiatrist at The Maudsley Hospital, where he runs a service for people with psychoses.

His research interests centre on the causes and treatment of affective and psychotic disorders. His recent work has focussed on understanding the role of dopamine and neuroinflammation in the development of psychosis, the effects of antipsychotic drugs, & the causes of cognitive impairments. This work has been recognised through a number of awards including the Royal College of Psychiatrists Researcher of the Year Award (2017), Schizophrenia International Research Society Rising Star Award 2013, European Psychiatric Association Biological Psychiatry Prize (2012), the Royal Society of Medicine Psychiatry Prize (2010), and the British Association of Psychopharmacology Clinical Psychopharmacology Prize (2007). In 2019 Web of Science named him as one of the most influential researchers in the world based on high impact papers over the last decade. He was made an honorary associate of the European College of Neuropsychopharmacology in 2006 and elected as a Fellow of the Academy of Medical Sciences in 2020.



David Kitchen

Pharmacist at Mersey Care NHS Trust Liverpool,
Merseyside, United Kingdom

A Clinical Hospital Pharmacist with 30 years experience, both in Australia and UK, in a variety of specialties, most recently Mental Health and Neurology and Neurosurgery. In current role as Senior Clinical Pharmacist responsible for Service Development linked in with and extensive Audit and Education Program which brought many significant improvements to the delivery of the Trust's medicines management. Most recently specifically focused on overhauling management of the novel atypical antipsychotic, Clozapine to manage risk, improve efficiency, safety and cost with a view to increasing the use of this superior therapy.

If you'd like to receive email invitation to the webinar and further information from us, please submit information below:

First Name

Last Name

Country

City

E-mail address

Phone number

Mylan (see company information in data protection notice) wishes to use your business contact data to provide you with scientific information and information on pharmaceutical products as well as events, webinars or surveys of Mylan group. In order to improve its emails, websites and information services, Mylan may track whether you received an email, opened it, clicked on any links, viewed or downloaded any documents in it. Your consent is voluntary. You can withdraw your consent at any time. The withdrawal of consent will not affect the lawfulness of processing based on consent before its withdrawal.

By signing below, you confirm you have read the data protection notice and consent to the processing of your business contact data for the above purposes.

Name & Surname

Signature

Date

Data protection notice according to Article 13 General Data Protection Regulation (GDPR):

XXX (indicate Mylan entity with full name and legal form as well as address) (herein referred to as "Mylan") is responsible for the processing of your personal data.

You can find further information on data protection including your right to access (Article 15 GDPR), rectification (Article 16 GDPR), erasure (Article 17 GDPR), restriction of processing (Article 18 GDPR), data portability (Article 20 GDPR), and right to lodge a complaint with a supervisory authority (Article 77 GDPR) in the data protection notice available at XXX (indicate link on Mylan website with corresponding full data protection notice).